• Home
  • About Us
  • Human Cardiomyocytes

History Introducing NEXEL’s History

2022’s

  • Apr
    The world's first ISO 17025 certification and KOLAS registration of drug cardiac safety analysis method using human iPSC derived cardiomyocyte FPDcF (Field Potential Duration corrected by Fridericia’s formula) rate of change
    Jan
    Received CiPA validation grant funded by MFDS (Ministry of Food and Drug Safety) and joined KiCSA (Korean iPSC Cardiac Safety Assessment)

2021’s

  • Dec
    Participated in ICH Guideline revision/HESI study as a cardiomyocyte provider
    Oct
    Established NEXEL USA (WA, US)
    Entered US Joint venture with Curi Bio (Celogics) (WA, US)
    Jul
    NP-011’s efficacy on NASH-Fibrosis demonstrated in the NHP disease model
    Apr
    Completed Series B bridge funding
    Apr
    Participated in publishing MFDS “Cardiovascular Safety Pharmacology evaluation method"
    Mar
    MoU signed with KangWon National University School of Medicine for collaborative research in the field of pulmonary fibrosis treatment
    Feb
    Registered "US Patent" for New Drug Candidate for Liver Fibrosis

2020’s

  • May
    MoU signed with Chonnam National University Hospital
    Apr
    Strategic partnership with Nanion Technologies to open reference lab in Korea for CardioExcyte96 FLEXcyte96

2019’s

  • Aug
    Completed Series B funding
    Aug
    Distribution agreement signed with KAC in the Japan for hiPSC-derived cell products
    May
    Novartis drug development team(VP level) visits NEXEL HQ
    Mar
    Distribution agreement signed with Cambridge Bioscience in the U.K. and Ireland for hiPSC-derived cell products

2018’s

  • Jun
    Innobiz Certification
    May
    Commercial license (non-exclusive) for hiPSC-derived cell products obtained from iPS Academia Japan
    Mar
    ISO9001 certification

2017’s

  • Dec
    Completed Series A funding
    Sep
    Invited to Novo Nordisk global collaboration business (with KOTRA)
    Aug
    MoU signed with T&R Biofab for the development of bioprinting technology using stem-cell derived cells
    May
    Distribution agreement with BOYA Medical for the distribution of iPSC-derived cell products
    Jan
    Domestic launch of cell products

2016’s

  • Dec
    Tech. transfer of 6 patents from Korea University Industry-Academic Cooperation Foundation
    Nov
    License-in of cardiomyocyte differentiation technology from KIT
    Sep
    MoU signed for the development of toxicology platfoms using stem-cell derived cells with Korea Institute of Toxicology (KIT)
    Mar
    Corporate affiliated research institute certified
    Feb
    Venture company certified

2015’s

  • May
    Name changed to NEXEL Co., Ltd.

2014’s

  • Nov
    Picked as family company to Korea University Life Sciences College
    Sep
    MoU signed with IMPLAD China

2013’s

  • Mar
    MoU signed with Korea University

2012’s

  • Sep
    Founding of NEXCELL Bio